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Abstract
Aims The aim of this pooled sub-analysis of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) and 
Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock (CULPRIT-SHOCK) trial was to compare the clini-
cal outcome of patients with acute myocardial infarction complicated by cardiogenic shock treated either with clopidogrel 
or the newer, more potent ADP-receptor antagonists prasugrel or ticagrelor.
Methods and results For the current analysis the primary endpoint was 1-year mortality and the secondary safety endpoint 
was moderate or severe bleedings until hospital discharge with respect to three different ADP-receptor antagonists. 856 
patients were eligible for analysis. Of these, 507 patients (59.2%) received clopidogrel, 178 patients (20.8%) prasugrel and 
171 patients (20.0%) ticagrelor as acute antiplatelet therapy. The adjusted rate of mortality after 1-year did not differ signifi-
cantly between prasugrel and clopidogrel (hazard ratio [HR]: 0.81, 95% confidence interval [CI] 0.60–1.09,  padj = 0.17) or 
between ticagrelor and clopidogrel treated patients (HR: 0.86, 95% CI 0.65–1.15,  padj = 0.31). In-hospital bleeding events 
were significantly less frequent in patients treated with ticagrelor vs. clopidogrel (HR: 0.37, 95% CI 0.20 -0.69,  padj = 0.002) 
and not significantly different in patients treated with prasugrel vs. clopidogrel (HR: 0.73, 95% CI 0.43 -1.24,  padj = 0.24).
Conclusion This pooled sub-analysis is the largest analysis on safety and efficacy of three oral ADP-receptor antagonists 
and shows that acute therapy with either clopidogrel, prasugrel or ticagrelor is no independent predictor of 1-year mortality. 
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Treatment with ticagrelor seems independently associated with less in-hospital moderate and severe bleeding events compared 
to clopidogrel. This finding might be due to selection bias and should be interpreted with caution.
Graphic abstract
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Abbreviations
AMI  Acute myocardial infarction
BARC  Bleeding academic research consortium
BMS  Bare-metal stent
CABG  Coronary artery bypass graft
CI  Confidence interval
DES  Drug-eluting stent
ECMO  Extracorporeal membrane oxygenation
HR  Hazard ratio
IABP  Intraaortic balloon pump
IQR  Interquartile range
LVEF  Left ventricular ejection fraction
OR  Odds ratio
PCI  Percutaneous coronary intervention
SAPS  Simplified acute physiology score
STEMI  ST-elevation myocardial infarction
RCT  Randomized controlled trial
Introduction
An important complication of acute myocardial infarction 
(AMI) is cardiogenic shock affecting around 5–10% of all AMI 
cases. It considerably worsens the prognosis [1, 2]. Recent 
randomized trials report a 30-day mortality rate in the range of 
40–52% in this entity [3]. Large registries even report mortal-
ity rates up to 70% at 1-year follow-up [2, 4]. As stated in the 
latest guidelines, primary percutaneous coronary intervention 
(PCI) is the standard reperfusion therapy for patients with AMI 
complicated by cardiogenic shock [5]. Subsequently, a dual 
antiplatelet therapy consisting of acetylsalicylic acid (ASA) 
and an adenosine-diphosphate (ADP)-receptor antagonist is 
indicated for patients treated by PCI [5]. The comparative 
safety, efficacy and antiplatelet action of different available 
ADP-receptor inhibitors in this patient cohort remain under-
studied, because the landmark trials comparing the more 
potent ADP-receptor inhibitors prasugrel and ticagrelor to 
clopidogrel excluded patients with cardiogenic shock [6, 7]. 
A sub-analysis of the Intraaortic Balloon Pump in Cardiogenic 
Shock II (IABP-SHOCK II) trial and accompanying registry 
indicated that the use of potent ADP-receptor antagonists—
predominantly prasugrel—is feasible and might not be harm-
ful in patients with cardiogenic shock complicating AMI [8, 
9]. Noteworthy, the number of studied patients treated with 
ticagrelor was negligible in the latter analyses due to its late 
approval in 2011. Thus, the aim of this pooled sub-analysis 
of the IABP-SHOCK II and Culprit Lesion Only PCI versus 
Multivessel PCI in Cardiogenic Shock (CULPRIT-SHOCK) 
trial was to investigate the safety and efficacy of the more 
vigorously and rapidly acting oral ADP-receptor antagonists 
prasugrel and especially ticagrelor.




The trial designs and results of both the IABP-SHOCK 
II and the CULPRIT-SHOCK trial have been published 
previously [3, 10]. Briefly, both studies were prospective, 
randomized, open-label, multicentre, controlled trials in 
patients with acute ST-elevation myocardial infarction 
(STEMI) and non-STEMI complicated by cardiogenic 
shock with the intention to undergo early revasculari-
zation (PCI or alternatively bypass surgery [only in the 
IABP-SHOCK II trial], for complete inclusion and exclu-
sion criteria see Thiele et al. [3, 10]). In total, 600 patients 
with AMI and cardiogenic shock were randomized to 
IABP or no IABP treatment in the IABP-SHOCK II trial. 
In the CULPRIT-SHOCK trial, 686 patients were ran-
domly assigned to undergo either culprit-lesion-only PCI 
with possible staged revascularization or immediate mul-
tivessel PCI.
Treatment with ADP‑receptor antagonists
The use of ADP-receptor antagonists was left to the discre-
tion of the treating physicians. There was neither a specific 
protocol nor randomization which drug to use or when and 
how to administer. The majority of the study patients were 
mechanically ventilated (53.9%) on admission and received 
the respective ADP-receptor antagonist via a naso-gastric 
tube to ensure enteral absorption.
Study endpoints, inclusion and exclusion criteria
The primary endpoint of this pooled, non-randomized 
observational sub-analysis was the post-procedural 1-year 
mortality with respect to three different ADP-receptor 
antagonists (clopidogrel vs. prasugrel vs. ticagrelor). The 
secondary safety endpoint was moderate or severe bleed-
ings according to GUSTO criteria [11] until hospital dis-
charge with respect to all three ADP-receptor antagonists. 
Further endpoints comprised 30-day mortality, stroke, 
myocardial infarction, all bleeding complications and 
severe or life-threatening bleedings as assessed according 
to GUSTO criteria during 1-year follow-up in surviving 
patients. Inclusion and exclusion criteria were adapted 
from the previously published [8] sub-analysis of the 
IABP-SHOCK II trial on ADP-receptor antagonists and 
were the following: Patients receiving either clopidogrel, 
prasugrel or ticagrelor as acute medical therapy qualified 
for inclusion into this subgroup-analysis. Patients who 
died before PCI, patients not receiving any ADP-receptor 
antagonist as acute antiplatelet therapy, patients with no 
information on ADP-receptor antagonist treatment and 
patients receiving any combination of clopidogrel, pras-
ugrel or ticagrelor simultaneously as acute antiplatelet 
therapy were excluded from analysis.
Statistical analysis
Detailed information on statistical analysis can be found in 
the Supplement. The impact of acute medication on mortal-
ity and bleeding was examined in unadjusted and adjusted 
regression analyses, the corresponding odds ratios (OR) or 
hazard ratios (HR) with 95%-confidence intervals (CI) are 
presented. We included variables in both models that show 
an association with at least one of the two outcome variables 
(in-hospital bleeding or 1-year bleeding) by univariate analy-
sis at p < 0.05. For the bleeding model, we used a logistic 
regression for the in-hospital events and a Cox proportional 
hazards regression for the bleeding complications until the 
end of follow-up. The following variables were entered in 
both multivariable models for bleeding complications: age 
and acute medication as fixed parameter, gender, previous 
myocardial infarction, resuscitation within 24 h before ran-
domization, mechanical ventilation, creatinine on admis-
sion [µmol/l], lactate > 2 mmol/l on admission, treatment 
with unfractionated heparin and active mechanical circula-
tory support. Concerning the model for mortality, variables 
entered in the model were age, female, previous myocardial 
infarction, previous PCI, previous coronary artery bypass 
graft (CABG) surgery, previous stroke, known renal insuf-
ficiency (glomerular filtration rate, GFR < 30 ml/min), 
resuscitation within 24 h before randomization, ST-segment 
elevation, creatinine on admission [µmol/l], heart rate [bpm] 




Information on patients who were excluded from the analy-
sis according to the exclusion criteria mentioned above 
are displayed in Supplemental Tables 8, 9, 10, 11, 12, 13, 
14, 15 and 16. After exclusion of 430 patients accord-
ing to the exclusion criteria, 856 patients were analysed. 
Of these, 507 patients (59.2%) received clopidogrel, 178 
patients (20.8%) prasugrel and 171 patients ticagrelor 
(20.0) as acute antiplatelet therapy (Fig. 1). The mean age 
of the clopidogrel (69 ± 12 years) and ticagrelor (69 ± 12 
years) group was similar, but patients receiving prasugrel 
were significantly younger (62 ± 11 years). The essential 
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baseline characteristics of all three subgroups are shown in 
Table 1; cf. Supplemental Table 2 for the extended base-
line characteristics of the cohorts. Regarding the clini-
cal presentation prior randomization during the primary 
trials, patients treated with prasugrel or ticagrelor were 
more often resuscitated before randomization (Prasugrel: 
n = 87/178, 48.9%; Ticagrelor: n = 85/171, 49.7%; Clopi-
dogrel: n = 204/506, 40.3%, p = 0.034), presented more 
often with STEMI (Prasugrel: n = 143/176, 81.3%; Ticagre-
lor: n = 118/167, 70.7%; Clopidogrel: n = 296/506, 58.5%, 
Fig. 1  Study flow chart of the 
pooled sub-analysis on ADP-
receptor antagonists in patients 
from the IABP-SHOCK II and 
CULPRIT-SHOCK trial. AMI 
acute myocardial infarction, 
PCI percutaneous coronary 
intervention
Table 1  Baseline characteristics of the study cohorts
This table shows baseline characteristics of the clopidogrel, the prasugrel and the ticagrelor subgroup. Data presented are means (± standard 
deviation, SD), medians [interquartile range, IQR] or numbers of patients (percentages)
*Body-mass index = weight in kilograms divided by the square of the height in meters
PCI percutaneous coronary intervention, CABG coronary artery bypass graft, GFR glomerular filtration rate, ASA acetylsalicylic acid, p-values: 








Age, years ± SD 69 ± 12 62 ± 11 69 ± 12  < 0.001
Female gender, n (%) 160 (31.6) 41(23.0) 42 (24.6) 0.044
Body-mass index*, median (IQR) 27.2 (24.5, 30.1) 26.3 (24.2, 28.9) 27.7 (24.7, 29.4) 0.77
Cardiovascular risk factors – no./total no. (%)
Current smoking 144/501 (28.7) 80/176 (45.5) 46/167 (27.5)  < 0.001
 Hypertension 353/504 (70) 112/178 (62.9) 92/170 (54.1)  < 0.001
 Hypercholesterolemia 187/503 (37.2) 67/178 (37.6) 55/169 (32.5) 0.51
 Diabetes mellitus 180/505 (35.6) 35/178 (19.7) 51/169 (30.2)  < 0.001
Morbidities
 Prior myocardial infarction, no./total no. (%) 121/506 (23.9) 35/178 (19.7) 19/170 (11.2) 0.002
 Prior stroke, no./total no. (%) 51/506 (10.1) 3/178 (1.7) 9/169 (5.3)  < 0.001
 Prior PCI, no./total no. (%) 108/506 (21.3) 39/178 (21.9) 22/170 (12.9) 0.043
 Renal impairment (GFR < 30 ml/min), no./total no. (%) 106/506 (20.9) 13/178 (7.3) 13/169 (7.7)  < 0.001
Chronic drug therapy, no./total no. (%)
 ASA 210/473 (44.4) 50/163 (30.7) 51/140 (36.4) 0.005
 Clopidogrel 72/474 (15.2) 10/162 (6.2) 6/135 (4.4)  < 0.001
 Prasugrel 1/474 (0.2) 3/162 (1.9) 0/135 (0.0) 0.028
 Ticagrelor 2/358 (0.6) 1/137 (0.7) 15/136 (11.0)  < 0.001
 Vitamin K-antagonists 31/473 (6.6) 4/161 (2.5) 3/134 (2.2) 0.034
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p < 0.001) and with lower levels of creatinine (Prasugrel: 
median = 102.27 [IQR 86.32, 133.30] µmol/l; Ticagrelor: 
median = 108.86 [IQR 91.05, 136.0] µmol/l; Clopidogrel: 
median = 116.50 [IQR 96.0, 151.0] µmol/l, p < 0.001) (Sup-
plemental Table 3) compared to clopidogrel. The treatment 
strategy did not differ between the cohorts with respect to the 
application of PCI, although bare-metal stents (BMS) were 
more frequently implanted in patients treated with clopi-
dogrel (Prasugrel: n = 41/171, 24.0%; Ticagrelor: n = 13/162, 
8.0%; Clopidogrel: n = 234/466, 50.2%, p < 0.001). Glyco-
protein (GP) IIb/IIIa inhibitors were more frequently used 
within the prasugrel (n = 79/178, 44.4%) and clopidogrel 
group (n = 189/507, 37.3%) compared to the ticagrelor 
group (n = 44/171, 25.7%, p = 0.001). In addition, a higher 
number of clopidogrel-treated patients required mechanical 
ventilation (n = 407/507, 80.3%, p = 0.023) in comparison to 
prasugrel (n = 126/177, 71.2%) or ticagrelor (n = 126/171, 
73.7%)-treated patients. There was no difference in the use 
of targeted temperature management between groups (Sup-
plemental Table 3).
Administration of clopidogrel, prasugrel 
and ticagrelor in IABP‑SHOCK II vs. CULPRIT SHOCK
In IABP SHOCK II 77.9% (n = 387) of patients were 
treated with clopidogrel, 19% (n = 93) with prasugrel and 
3.4% (n = 17) with ticagrelor. In CULPRIT-SHOCK 33.4% 
(n = 120) of patients were treated with clopidogrel, 24% 
(n = 85) with prasugrel and 43% (n = 154) with ticagrelor 
(p < 0.0001, Supplemental Table 1).
Clinical outcome
The unadjusted rates of mortality at 1-year follow-up, as well 
as ischemic and bleeding events of all three subgroups at 
30-days follow-up are listed in Table 2. The unadjusted all-
cause 1-year mortality was lowest in prasugrel, followed by 
ticagrelor and highest in clopidogrel treated patients (34.9% 
[61/175] vs. 48.0% [82/171] vs. 55.9% [283/506] of patients, 
p < 0.001), Fig. 2. There was also a lower unadjusted all-
cause 30-day mortality in prasugrel, followed by ticagrelor 
and highest in clopidogrel treated patients (29.8% [53/178] 
vs. 42.1% [72/171] vs. 43.9% [222/506], p < 0.01). The inci-
dence of repeat myocardial infarction and ischemic stroke 
did not differ significantly between all three subgroups. 
Table 2  Clinical outcome at 
follow-up
This table shows unadjusted death, ischemic and bleeding events of all three cohorts at 30 days and at 
1-year follow-up. Data presented are numbers of patients (percentages). PCI percutaneous coronary inter-
vention. p-values: Pearson chi-squared test or Mann–Whitney–Wilcoxon test








 Death ≤ 30 days 222/506 (43.9) 53/178 (29.8) 72/171 (42.1) 0.004
 Postprocedural death ≤ 30 days 206/490 (42.0) 51/176 (29.0) 67/166 (40.4) 0.009
 Renal replacement therapy ≤ 30 days 99/507 (19.5) 29/178 (16.3) 20/171 (11.7) 0.060
Events by survivors (≤ 30 days)
 Myocardial infarction ≤ 30 days 8/284 (2.8) 1/125 (0.8) 1/99 (1.0) 0.30
 Stroke ≤ 30 days 2/284 (0.7) 5/125 (4.0) 2/99 (2.0) 0.065
 PCI ≤ 30 days 17/284 (6.0) 10/125 (8.0) 4/99 (4.0) 0.47
1-year events
 Death ≤ 365 days 283/506 (55.9) 61/175 (34.9) 82/171 (48.0)  < 0.001
 Postprocedural death ≤ 365 days 267/490 (54.5) 59/173 (34.1) 77/166 (46.4)  < 0.001
Events by survivors (≤ 365 days)
 Myocardial infarction ≤ 365 days 13/223 (5.8) 6/114 (5.3) 2/89 (2.2) 0.41
 Stroke ≤ 365 days 5/223 (2.2) 5/114 (4.4) 3/89 (3.4) 0.55
 PCI ≤ 365 days 46/223 (20.6) 35/114 (30.7) 24/89 (27.0) 0.11
 Moderate and severe bleeding ≤ 365 36/223 (16.1) 14/114 (12.3) 6/89 (6.7) 0.081
 Severe bleeding ≤ 365 days 5/223 (2.2) 6/114 (5.3) 0/89 (0.0) 0.057
 Moderate bleeding ≤ 365 days 34/223 (15.2) 9/114 (7.9) 6/89 (6.7) 0.039
 In-hospital bleeding events 94/507 (18.5) 25/177 (14.1) 17/171 (9.9) 0.022
 Severe/life-threatening 18/507 (3.6) 12/177 (6.8) 7/171 (4.1) 0.19
 Moderate 83/507 (16.4) 16/177 (9.0) 11/171 (6.4)  < 0.001
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Table 3 depicts a multivariate Cox regression model for 
30-day and 1-year mortality. No significant differences were 
observed concerning the mortality risk with respect to the 
ADP-receptor antagonist applied. For 1-year mortality the 
adjusted hazard ratio was 0.81 (95% CI 0.60–1.09, p = 0.17) 
for patients treated with prasugrel vs. clopidogrel and 0.86 
(95% CI 0.65–1.15, p = 0.31) for patients treated with tica-
grelor vs. clopidogrel (see also Tables 4, 5).    
Unadjusted moderate and severe bleeding events of 
surviving patients during 1-year follow-up were not 
significantly different and numerically highest in clopi-
dogrel (16.1% [36/223]) vs. prasugrel (12.3% [14/114]) vs. 
ticagrelor (6.7% [6/89])-treated patients, p = 0.081). Moder-
ate bleeding events during 1-year follow-up were signifi-
cantly different and highest in clopidogrel (15.2% [34/223]) 
compared to prasugrel (7.9% [9/114]) and ticagrelor (6.7% 
[6/89], p = 0.039) treated patients. The rate of in-hospital 
bleeding events was significantly higher in clopidogrel vs. 
prasugrel and vs. ticagrelor treated patients (18.5% [94/507] 
vs. 14.1% [25/177] vs. 9.9% [17/171], p = 0.022), Figure 3. 
Fig. 2  The Figure shows the survival curve during 1-year follow-up period in patients treated with clopidogrel (blue line), prasugrel (red line) or 
ticagrelor (green line)
Table 3  Cox regression model of post-procedural 30- day and 1- year mortality
This table shows the multivariable Cox regression model of post-procedural 30- day and 1-year mortality with the different ADP-receptor inhibi-
tors as dependent variable in comparison to clopidogrel. Adjusted odd ratios were calculated with an adjustment for the variables shown in the 
methods section. P-values: Pearson chi-squared test or Mann–Whitney–Wilcoxon test
30-day mortality Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Prasugrel vs. Clopidogrel 0.62 (0.46–0.84) 0.0022 0.88 (0.63–1.22) 0.43
Ticagrelor vs. Clopidogrel 0.96 (0.73–1.26) 0.76 0.91 (0.66–1.26) 0.57
1-year mortality Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Prasugrel vs. Clopidogrel 0.54 (0.41–0.72)  < 0.0001 0.81 (0.60–1.09) 0.17
Ticagrelor vs. Clopidogrel 0.83 (0.65–1.07) 0.16 0.86 (0.65–1.15) 0.31
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This effect was mainly driven by a difference in moderate 
in-hospital bleedings in clopidogrel vs. prasugrel and vs. 
ticagrelor treated patients (16.4% [83/507] vs. 9.0% [16/177] 
vs. 6.4% [11/171], p < 0.001). In a multivariate Cox regres-
sion analysis of in-hospital moderate or severe bleeding 
events in surviving patients, ticagrelor was associated with 
Table 4  Regression analysis of bleeding events
This table shows the regression analyses of bleeding events with the different ADP-receptor inhibitors as dependent variable in comparison to 
clopidogrel. Adjusted odds and hazard ratios were calculated with an adjustment for the variables shown in the methods section. P-values: Pear-
son chi-squared test or Mann–Whitney–Wilcoxon test
Hospital bleeding events (moderate 
& severe)
Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Prasugrel vs. Clopidogrel 0.72 (0.45–1.17) 0.18 0.73 (0.43–1.24) 0.24
Ticagrelor vs. Clopidogrel 0.49 (0.28–0.84) 0.01 0.37 (0.20–0.69) 0.002
1—year bleeding events (moderate & 
severe)
Unadjusted HR (95% CI) P value Adjusted HR (95% CI) P value
Prasugrel vs. Clopidogrel 0.74 (0.49–1.11) 0.14 0.83 (0.54–1.28) 0.40
Ticagrelor vs. Clopidogrel 0.50 (0.30–0.83) 0.007 0.43 (0.25–0.72) 0.002
Table 5  Cox regression model of 30- day/ 1- year mortality and in- hospital/ 1-year bleeding events comparing Prasugrel vs. Ticagrelor
This table shows the unadjusted and adjusted Cox regression model of 30- day and 1- year mortality, as well as in- hospital and 1- year bleed-
ing events comparing Prasugrel versus Ticagrelor; an unadjusted and adjusted regression analyses and corresponding odds ratio (OR) or hazard 
ratio (HR) with 95%-confidence interval (CI) are presented. All variables with p-value < 0.05 from the univariate comparison were entered in 
the multivariable models. For the bleeding model, a logistic regression for the in-hospital events and a Cox proportional hazards regression for 
the bleeding complications until the end of follow-up was used. Adjusted odd ratios for mortality were calculated with an adjustment for the 
following variables: Age, gender, previous myocardial infarction, known chronic kidney diseases (eGFR < 30 ml/min), previous PCI, previous 
CABG surgery, previous stroke, ST-segment elevation, creatinine on admission [µmol/l], heart rate before PCI, systolic blood pressure before 
PCI, SAPS II and resuscitation within 24 h before randomization. Adjusted odds and hazard ratios for bleeding events were calculated with an 
adjustment for the following variables: Age, gender, previous myocardial infarction, Creatinine on Admission [µmol/l], mechanical ventilation, 
resuscitation within 24 h before randomization, unfractionated heparin as acute drug therapy, serum lactate > 2 mmol/l on admission and active 
assist devices. HR hazard ratio, OR odds ratio, CI confidence interval, eGFR estimated glomerular filtration rate, PCI percutaneous coronary 
intervention, CABG coronary artery bypass graft, SAPS II simplified acute physiology score II. P-values: Pearson chi-squared test or Mann–
Whitney–Wilcoxon test
Unadjusted HR (95%CI) p-value Adjusted HR (95%CI) p-value
Endpoints
 Post-procedural 30-day mortality Ticagrelor vs. Prasugrel 1.57 (1.09–2.26) 0.016 1.07 (0.72–1.61) 0.73
Prasugrel vs. Clopidogrel/Tica-
grelor
0.58 (0.43–0.77)  < 0.001 0.96 (0.70–1.30) 0.77
Ticagrelor vs. Clopidogrel/Prasu-
grel
0.96 (0.74–1.24) 0.75 0.87 (0.65–1.18) 0.37
 Post-procedural 365-day mortality Ticagrelor vs. Prasugrel 1.56 (1.11–2.18) 0.01 1.09 (0.75–1.58) 0.65
Prasugrel vs. Clopidogrel/Tica-
grelor
0.56 (0.43–0.72)  < 0.0001 0.89 (0.67–1.17) 0.40
 In- hospital severe/moderate 
bleeding
Ticagrelor vs. Prasugrel 0.67 (0.35–1.29) 0.23 0.51 (0.25–1.05) 0.068
Prasugrel vs. Clopidogrel/Tica-
grelor
0.79 (0.51–1.25) 0.31 0.83 (0.51–1.34) 0.44
Ticagrelor vs. Clopidogrel/Prasu-
grel
0.51 (0.30–0.86) 0.01 0.46 (0.26–0.81) 0.006
 Severe /moderate bleeding 365- 
days
Ticagrelor vs. Prasugrel 0.68 (0.38–1.22) 0.20 0.51 (0.28–0.95) 0.033
Prasugrel vs. Clopidogrel/Tica-
grelor
0.76 (0.52–1.12) 0.17 0.91 (0.61–1.36) 0.65
Ticagrelor vs. Clopidogrel/Prasu-
grel
0.50 (0.31–0.81) 0.005 0.46 (0.28–0.75) 0.002
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a significantly lower risk compared to clopidogrel (Odds 
ratio [OR]: 0.46, 95% CI 0.23–0.90, p = 0.024) (Tables 4, 5, 
Supplemental Table 7). There was no significant difference 
between ticagrelor- and prasugrel-treated patients (OR: 0.58, 
95% CI 0.27–1.23, p = 0.16). Likewise, no significant dif-
ference was seen in the prasugrel vs. the clopidogrel group 
after adjustment (OR: 0.79, 95% CI 0.46–1.35, p = 0.39). 
Concerning moderate or severe bleeding events in survivors 
during 1-year follow-up, ticagrelor was associated with a 
significantly lower risk compared to both clopidogrel (HR: 
0.43, 95% CI 0.25–0.72, p = 0.002) and prasugrel (HR: 
0.51, 95% CI 0.28–0.95, p = 0.033). There was no signifi-
cant difference in the 1-year bleeding risk between prasug-
rel- vs. clopidogrel-treated patients (HR 0.83 (CI 0.54–1.28, 
p = 0.40).
Discussion
The key findings of our pooled sub-analysis of the rand-
omized trials IABP-SHOCK II and CULPRIT-SHOCK 
are: (1) The frequency of the three different oral adminis-
tered ADP-receptor antagonists changed during the study 
periods of both trials as clopidogrel was the predominant 
ADP-receptor antagonist in IABP-SHOCK II and ticagrelor 
in CULPRIT-SHOCK; (2) there was no statistically signifi-
cant difference in the adjusted mortality risk in prasugrel vs. 
clopidogrel and in ticagrelor vs. clopidogrel treated patients; 
(3) the adjusted rate of in-hospital and 1-year bleedings 
was significantly lower in ticagrelor vs. clopidogrel treated 
patients.
This work represents the largest analysis of the safety and 
efficacy of the different orally available ADP-receptor antag-
onists clopidogrel, prasugrel and ticagrelor in patients with 
AMI complicated by cardiogenic shock. The landmark trials 
comparing clopidogrel vs. prasugrel [6], or vs. ticagrelor, 
Fig. 3  The Figure shows the bleeding curve during 30-day follow-up period in patients treated with clopidogrel (blue line), prasugrel (red line) 
or ticagrelor (green line)
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respectively [7], excluded patients with cardiogenic shock 
prior to randomization. Just recently, the ISAR-REACT-5 
trial demonstrated the superiority of a no pre-treatment 
strategy with prasugrel loading after coronary angiogra-
phy over a pre-treatment strategy with ticagrelor in patients 
with AMI concerning 1-year adverse cardiovascular events. 
Whether the strategy or the drug investigated in this trial 
was superior cannot be concluded without a 2 × 2 factorial 
design. Moreover, only 1.6% of the study participants suf-
fered from cardiogenic shock [12]. Hence, there was a lack 
of evidence on the safety and efficacy of oral ADP-receptor 
antagonists in cardiogenic shock patients. Data are mainly 
limited to a previous sub-analysis of the IABP-SHOCK 
II trial showing that the newer and more potent prasugrel 
can be safely administered without harm in these patients. 
However, ticagrelor was barely investigated since only 3.4% 
of patients (n = 17) were treated with ticagrelor in IABP-
SHOCK II. Since ticagrelor has become the predominantly 
administered ADP-receptor inhibitor in CULPRIT-SHOCK, 
we could now investigate safety and efficacy of this direct 
acting drug in this combined patient cohort including 170 
patients on ticagrelor treatment (Supplemental Table 1). Of 
note, the use of ticagrelor—instead of prasugrel which is not 
recommended in patients above 75 years of age and below 
60 kg of body weight —is not restricted and patient charac-
teristics were more similar to the clopidogrel group, which is 
in large contrast to the prasugrel group in our investigation. 
However, adjusted mortality rates of all 3 cohorts in our sub-
analysis were comparable and, therefore, correspond to the 
results of the IABP-SHOCK II sub-analysis [8].
Bleeding complications in general occur frequently in 
patients with AMI complicated by cardiogenic shock, and 
they are associated with mortality and are reported as high 
as in our study [13]. Cardiogenic shock patients are predis-
posed to suffer specifically from ICU-bleeding events due 
to their temporary need for resuscitation, requiring repeated 
chest compression and frequent puncture of both arteries 
and central veins. Temporary mechanical circulatory sup-
port devices, such as veno-arterial extracorporeal mem-
brane oxygenation (ECMO) or co-axial pumps requiring 
large bore vascular access and therapeutic anticoagulation 
have also emerged as pivotal risk factors for bleeding events 
[14, 15]. By including patients from two large randomized 
controlled trials in our sub-analysis, ticagrelor was shown 
to be an independent predictor of lower bleeding risk com-
pared to clopidogrel. Still, this finding might be explained by 
higher comorbidity of the clopidogrel group which cannot 
be completely eliminated by statistical adjustment. How-
ever, although ticagrelor was associated with less bleeding 
events compared to clopidogrel this did not translate into a 
reduced mortality—a finding which requires investigation 
in future trials.
Pharmacological effects of ADP‑receptor 
antagonists in cardiogenic shock and their role 
in bleeding events
There are some known pharmacodynamic disparities with 
respect to the antiplatelet action of clopidogrel, prasugrel 
and ticagrelor in AMI patients suffering from cardiogenic 
shock. The available data are limited to smaller and pre-
dominantly retrospective cohorts [16]. A reduced enteral 
absorption is a key drawback of oral ADP-receptor antago-
nists in cardiogenic shock [17]. Therefore, cangrelor, an 
intravenous ADP-receptor antagonist requiring no bioacti-
vation in-vivo, might pose a suitable alternative [17] and is 
currently under investigation in the ongoing DAPT-SHOCK-
AMI (NCT03551964) trial. Cangrelor did not have FDA-
approval during the IABP-SHOCK-II trial and was barely 
used in the CULPRIT-SHOCK trial. Thus, we excluded this 
drug from our current analysis. Still, clopidogrel is known 
to be associated with a relatively slow onset of action and 
to induce lower levels of platelet inhibition in patients with 
AMI complicated by cardiogenic shock [18]. Consequently, 
current guidelines recommend to use prasugrel or ticagre-
lor in these patients. As our data show, the choice of the 
ADP-receptor antagonist on the other hand does not seem 
to be decisive for the bleeding risk in patients with AMI 
complicated by cardiogenic shock. Maybe, not the choice 
of the ADP-receptor antagonist itself might drive bleeding 
events, but rather the individual effect of the drug on platelet 
aggregation as reflected by differences in the quantifiable 
platelet reactivity. Still, this would not explain the differ-
ences in bleeding complications observed in this study since 
it is plausible that ticagrelor would have achieved a higher 
level of platelet inhibition than clopidogrel. An investiga-
tion, whether switching patients with low platelet reactivity 
on potent ADP-receptor antagonist to the weaker clopidogrel 
leads to fewer bleeding events in cardiogenic shock patients, 
appears to be very interesting—a strategy which was already 
shown to be safe in AMI patients without cardiogenic shock 
in the Testing Responsiveness to Platelet Inhibition on 
Chronic Antiplatelet Treatment For Acute Coronary Syn-
dromes (TROPICAL-ACS) trial [19].
Limitations
This study is a non-randomized pooled post-hoc sub-analysis 
with all its known limitations. Given the limited number of 
patients and the major differences in baseline and proce-
dural characteristics arising from a pooled analysis of two 
heterogeneous trials, the possibility of type 2 errors cannot 
be completely excluded. Although the differences in patient 
characteristics highlight a treatment bias between the three 
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subgroups, a risk adjusted analysis was used to take these 
limitations into account. No information was available on the 
prescription of ADP- receptor antagonists after discharge. 
430 patients had to be excluded from this analysis according 
to exclusion criteria. Moreover, there was no platelet func-
tion monitoring of patients so that we could not analyse the 
pharmacodynamics of the different ADP-receptor antago-
nists. Likewise, the effects of shock on enteral absorption, 
as wells as an impaired activation of prodrugs (clopidogrel, 
prasugrel) were not addressed. No data were available to 
reflect the true renal function at baseline and during fol-
low-up since the eGFR can only be calculated in a steady 
state. Although we could not analyse bleeding complica-
tions according to the latest BARC criteria, the classification 
according to GUSTO criteria was available in both trials.
Summary
To date, this study represents the largest analysis with 
respect to the application of different ADP-receptor antag-
onists in patients with AMI complicated by cardiogenic 
shock. There were no significant differences in terms of 
mortality rates between patients treated with clopidogrel, 
prasugrel and ticagrelor after adjustment for differences 
in baseline characteristics. In addition, ticagrelor appears 
to be associated with a lower rate of in-hospital bleeding 
events compared to clopidogrel. However, the results must 
be interpreted with caution due to the limitations inherit to 
non-randomized pooled post-hoc sub-analyses. Contempo-
rary studies in stable patients connect bleeding events rather 
to the pharmacological effect in the individual patient as 
opposed to a specific ADP-receptor antagonist. Thus, future 
trials may test whether a platelet reactivity guided choice of 
the ADP- receptor antagonist might be beneficial in terms of 
reducing bleeding events in patients with cardiogenic shock.
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